Background Diagnosis of metastatic castrate resistant prostate cancer (mCRPC) with current
biomarkers is difficult and often results in unnecessary invasive procedures as well as over …

When advanced prostate cancer recurred during hormonal therapy and became the
castration‐resistant prostate cancer,“vintage hormonal therapy,” such as antiandrogen …

Androgen receptor splice variant-7 (AR-V7) expression in circulating tumor cells (CTCs) in
metastatic castration-resistant prostate cancer (mCRPC) is associated with abiraterone and …

First worldwide family litigation filed litigation https://patents. darts-ip. com/? family=
67140292&utm_source= google_patent&utm_medium= platform_link&utm_campaign …

Abstract Reports of Bone Scan Index (BSI) calculations as imaging biomarkers to predict
survival in patients with metastatic castration-resistant prostate cancer (mCRPC) have been …

BACKGROUND We sought to identify potential clinical variables associated with outcomes
after radium‐223 therapy in routine practice. METHODS Consecutive non‐trial mCRPC …

The aim of this study was to investigate the prognostic value of the quantitative assessment
of skeletal tumor burden on bone scintigraphy (Bone Scan Index [BSI]) in patients who have …

Simple Summary Standardized reading schemes, the use of indicators derived from medical
images and the use of deep learning-based algorithms become very popular in medical …

Objective To determine prognostic factors including the Bone Scan Index in prostate cancer
patients receiving standard hormonal therapy and chemotherapy. Methods This multicenter …

Described herein is a platform and supported graphical user interface (GUI) decision-
making tools for use by medical practitioners and/or their patients, eg, to aide in the process …